Humacyte Secures $77.5 Million Credit Facility to Support Bioengineered Tissue Platform Expansion
核心洞察
Humacyte announced a four-year credit facility with Avenue Capital Group (搜索) providing up to $77.5 million in financing, with $40 million funded immediately to retire existing debt.
The company plans to expand Symvess (搜索) commercialization in U.S. and international markets while advancing its V012 Phase 3 dialysis trial in 2026.
Humacyte will commence the first human study of its coronary tissue engineered vessel for coronary bypass graft surgery next year.
Humacyte, Inc. (Nasdaq: HUMA) has secured a strategic credit facility worth up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (搜索), to support the expansion of its bioengineered human tissue platform. The four-year credit agreement includes an initial $40 million tranche that was fully funded at closing, with proceeds primarily used to retire the company's existing debt facility.
The financing structure includes two additional tranches totaling up to $37.5 million, available to Humacyte subject to meeting specific revenue targets, regulatory approvals, liquidity conditions, and lender approvals for the third tranche. This arrangement provides the commercial-stage biotechnology company with flexible, non-dilutive financing to support its growth trajectory.
Strategic Focus on 2026 Milestones
Dale Sander, Chief Financial Officer of Humacyte, highlighted the company's ambitious plans for 2026, stating: "We are looking forward to an exciting 2026, including our plans for expanded use of Symvess (搜索)® within the U.S. and international markets, interim results from our V012 Phase 3 trial in dialysis, and commencement of the first human study of our coronary tissue engineered vessel (CTEV (搜索)) in coronary bypass graft surgery."
The company's Symvess (搜索) product, based on its acellular tissue engineered vessel (ATEV) technology, received FDA approval for vascular trauma (搜索) indication in December 2024. This approval marked a significant milestone for Humacyte's bioengineered tissue platform, which develops universally implantable human tissues designed to treat a wide range of diseases, injuries, and chronic conditions.
Advanced Clinical Pipeline
Humacyte's ATEV technology is currently advancing through late-stage clinical trials for multiple vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease (搜索). The company's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation.
The ATEV platform has garnered significant regulatory recognition, with RMAT designations for urgent arterial repair following extremity vascular trauma (搜索) and advanced peripheral artery disease (搜索). Additionally, the ATEV received priority designation for vascular trauma treatment from the U.S. Secretary of Defense, underscoring its potential military and civilian applications.
Expanding Therapeutic Applications
Beyond vascular applications, Humacyte is pursuing preclinical development across multiple therapeutic areas, including coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes (搜索), and various novel cell and tissue applications. The upcoming first human study of the coronary tissue engineered vessel represents a significant expansion of the platform's potential applications.
Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund, expressed confidence in the partnership: "We are excited to partner with Humacyte as it embarks on its next chapter of growth. Symvess (搜索) is addressing significant patient needs and we are looking forward to supporting them in achieving success."
The Avenue Venture Debt Funds focus on providing creative financing solutions to high-growth, venture capital-backed technology and life science companies, particularly targeting the underserved market segment between commercial banks and larger debt funds. Avenue Capital Group (搜索) manages more than $10 billion in assets under management globally.